Advertisement
Document › Details
Haya Therapeutics SA. (7/18/24). "Press Release: Haya Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer". Lausanne & San Diego, CA.
Organisation | Haya Therapeutics S.A. | |
Organisation 2 | Roche pRED (Pharma Research and Early Development unit) | |
Group | Roche (Group) | |
Product | HTX-001 (Haya Therapeutics) | |
Product 2 | drug development | |
Person | Linn, Michelle (Linnden Communications formerly Bioscribe) | |
Person 2 | Ounzain, Samir (Haya Therapeutics 202105 CEO + Co-Founder) | |
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions.
Under the terms of the collaboration, HAYA will receive an upfront payment, including an equity investment, and is eligible to receive up to an aggregate $1 billion in pre-clinical, clinical and commercial milestone payments, as well as royalties on product sales.
HAYA’s proprietary regulatory genome discovery platform enables the identification of tissue-, disease- and cell-specific long non-coding RNA (lncRNA) targets and the development of RNA-targeting therapies, with potentially better efficacy and less toxicity than current treatments, to reprogram disease-driving cell states. This collaboration will utilize HAYA’s full-stack regulatory genome platform to identify, characterize and validate multiple novel lncRNA targets for the potential development of new treatments for obesity and related metabolic disorders.
"This partnership with Lilly demonstrates the significant advances we have made with our revolutionary regulatory genome RNA-guided platform and validates the potential of targeting lncRNA for chronic conditions," said Samir Ounzain, CEO, HAYA Therapeutics. "We look forward to working closely with Lilly, an established leader in developing treatments for metabolic diseases, to help bring patients novel disease-modifying therapeutics that could offer greater efficacy, safety and accessibility than currently available treatments."
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA’s lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues.
HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego. For more information on the company, please visit our website at www.hayatx.com. Follow us on X and LinkedIn.
Media Contacts:
Michelle Linn
Email: michelle@linndencom.com
Record changed: 2024-09-26 |
Advertisement
More documents for Haya Therapeutics S.A.
- [1] Haya Therapeutics SA. (9/4/24). "Press Release: Haya Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform". Lausanne & San Diego, CA....
- [2] Haya Therapeutics SA. (7/1/24). "Press Release: Haya Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award". Lausanne & San Diego, CA....
- [3] Haya Therapeutics SA. (2/9/22). "Press Release: Haya Therapeutics Establishes U.S. Location. Haya Closes US$5M Seed Extension". Lausanne & San Diego, CA....
- [4] Haya Therapeutics SA. (8/10/21). "Press Release: Haya Therapeutics Announces Scientific Advisory Board". Lausanne....
- [5] Haya Therapeutics SA. (5/20/21). "Press Release: Haya Therapeutics Completes CHF 18 Million Seed Financing to Advance Anti-fibrotic Therapies Targeting Long Non-Coding RNAs". Lausanne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top